J.P. Courrèges

Liraglutide, a Long-Acting Human Glucagon-Like Peptide-1 Analog, Given as Monotherapy Significantly Improves Glycemic Control and Lowers Body Weight Without Risk of Hypoglycemia in Patients With Type 2 Diabetes

Tina Vilsbøll, Milan Zdravkovic, T Le-Thi et al. · Diabetes Care · 2007 · 467 citations · Full text

A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes

Michael A. Nauck, John R. Petrie, Giorgio Sesti et al. · Diabetes Care · 2015 · 219 citations · Full text

The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial

Sultan Linjawi, Bruce W. Bode, Louis Chaykin et al. · Diabetes Therapy · 2016 · 130 citations · Full text

Insulin Degludec/Insulin Aspart Administered Once Daily at Any Meal, With Insulin Aspart at Other Meals Versus a Standard Basal-Bolus Regimen in Patients With Type 1 Diabetes

Irl B. Hirsch, Bruce W. Bode, J.P. Courrèges et al. · Diabetes Care · 2012 · 75 citations · Full text